Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA), a Fortune 500 leader in kidney care and dialysis services, maintains this dedicated news hub for stakeholders tracking its clinical advancements and financial performance. Access consolidated updates on earnings reports, strategic partnerships, and regulatory developments shaping the company’s position in global healthcare markets.
This resource serves investors and industry observers seeking timely insights into DaVita’s operational milestones, including innovations through DaVita Clinical Research and expansions of its integrated care network. Content spans press releases on treatment protocols, Medicare reimbursement updates, and collaborations with healthcare providers.
Key categories include quarterly financial disclosures, acquisitions in outpatient care, clinical trial outcomes, and quality improvement initiatives. Bookmark this page for streamlined access to verified updates about DaVita’s efforts to advance kidney disease management across 3,000+ U.S. dialysis centers.
DaVita Inc. (NYSE: DVA) has scheduled its quarterly conference call to discuss first-quarter results on May 8, 2023, at 5:00 p.m. Eastern Time. The results will be released after the market closes on the same day. The call will be available via webcast on the DaVita investor relations webpage. Investors can join by dialing 877-918-6630 (or 517-308-9042 internationally) and using the password 'Earnings'. For those unable to attend, a replay will be accessible on DaVita's website without a telephone replay option. As of December 31, 2022, DaVita served 200,000 patients across 2,724 outpatient dialysis centers in the U.S. and operated 350 centers in 11 other countries, focusing on improving care delivery and clinical outcomes for kidney health.
FAQ
What is the current stock price of Davita (DVA)?
What is the market cap of Davita (DVA)?
